Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

BioNTech SE

35 indications, side-by-side phase, drug & LoA

$86.15

-0.35 (-0.4%)

A 82Pipeline Score Fair Value Biotech · Commercial
Market Cap
23.30 B
EPS
-5.87
P/E Ratio
-
Value Trade
58.32 M
2.04 %
Week
-18.02 %
1 Month
-15.61 %
3 Month
-5.52 %
6 Month
-53.35 %
5 Year
458.42 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
1.21 M
52 Week Range
79.52 - 124
% held by Insiders
0.37 %
% held by Institutions
19.64 %
Enterprise Value
6.79 B
Total Shares
252.88 M
Short %
0.9 %
Float Shares
251.94 M
Company Description
Employees:7,807
https://www.biontech.de

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 interim results example
gotistobart (BNT316/ONC-392) metastatic squamous non-small cell lung cancer (NSCLC) progressed after platinum-based chemotherapy and PD-(L)1 therapy
Phase 3
—
Biologics
Oncology
gotistobart (BNT316/ONC-392) metastatic squamous non-small cell lung cancer (NSCLC) progressed after platinum-based chemotherapy and PD-(L)1 therapy
Phase 3
—
Biologics
Oncology
gotistobart (BNT316/ONC-392) metastatic squamous non-small cell lung cancer (NSCLC) progressed after platinum-based chemotherapy and PD-(L)1 therapy
Phase 3
—
Biologics
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A82
Pipeline Score
$63.2B
Pipeline Value
Fair Value
Valuation Signal
57
Drugs Scored
2.7x
rNPV / MCap
Top 97%
Mid Cap
(rank 28 of 905)
Percentile Rank
BioNTech SE earns an A-grade pipeline score (82/100), with $74.9B risk-adjusted pipeline value, led by BNT162b2 in SARS-CoV-2 Infection (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
BNT162b2
Monoclonal antibody		COVID-19Phase 3NCT0722238465% $10.0B ACTIVE NOT_RECRUITING 6,357 SLOW D (34) Jul 31, 2026LOW_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
BNT327
small cell lung cancer,non-small cell lung cancer,triple-negative breast cancer,mesothelioma
Phase 2/3
2025-08-05
BNT327
small cell lung cancer,non-small cell lung cancer,triple-negative breast cancer,mesothelioma
Phase 2/3
2025-08-05
BNT327
small cell lung cancer,non-small cell lung cancer,triple-negative breast cancer,mesothelioma
Phase 2/3
2025-08-05
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in BNTX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
BioNTech SE (BNTX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BNTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
BNTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
BNTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest BioNTech SE (BNTX) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How BNTX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
COVID-19 #2 of 16 PHASE 3 BNT162b2
PFE MRK IVVD
$12.31B 0.96 CONTENDER
Tuberculosis #3 of 4 PHASE 1 BNT164a1 + BNT164b1
VTRS JNJ HBIO
$2.27B 0.95 CONTENDER
Breast Cancer #5 of 94 PHASE 3 DB-1303/BNT323 + T-DM1
MRK AZN GILD
$10.85B 0.86 LEADER
Lung Cancer #5 of 79 PHASE 3 Pumitamig + Atezolizumab + Etoposide + Carboplatin
MRK GILD AMGN
$28.1B 0.89 LEADER
Endometrial Cancer #5 of 48 PHASE 3 BNT323/DB-1303 + Doxorubicin + Paclitaxel + Docetaxel
MRK AZN GILD
$31.09B 0.92 CONTENDER
HIV / AIDS #5 of 14 PHASE 1 BNT351
MRK GILD GSK
—0.97 CONTENDER
Vaccines (Prophylactic) #6 of 9 PHASE 2 BNT166a
GSK SNY PCVX
$96.24B 0.98 FOLLOWER
Non-Small Cell Lung Cancer #8 of 88 PHASE 3 Gotistobart + Docetaxel
MRK AMGN AZN
$28.1B 0.84 LEADER
Pancreatic Cancer #10 of 73 PHASE 2 Pumitamig + Nab-paclitaxel + Gemcitabine + mFOLFIRINOX
RVMD RCUS AZN
$3.7B 0.88 FOLLOWER
Prostate Cancer #11 of 53 PHASE 3 BNT324 + Docetaxel + Prednisone/prednisolone
MRK AZN PFE
$25.12B 0.96 CONTENDER
Bacterial Infections #13 of 31 PHASE 1 BNT163
PFE SNY GRFS
$10.5B 0.97 FOLLOWER
Head and Neck Cancer #15 of 63 PHASE 2 BNT113 + Pembrolizumab
AZN GSK MRK
$10.2B 0.89 FOLLOWER
Liver Cancer #15 of 37 PHASE 2 PM8002 + FOLFOX regimen
AZN BMY EXEL
$4.8B 0 FOLLOWER
Colorectal Cancer #17 of 82 PHASE 2 RO7198457
ABBV BMY MRK
$7.68B 0.91 CONTENDER
Bladder Cancer #17 of 47 PHASE 2 Autogene Cevumeran + Nivolumab + Saline
AZN BMY JNJ
$0.33B 0.84 FOLLOWER